ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 177 filers reported holding ENANTA PHARMACEUTICALS INC in Q3 2019. The put-call ratio across all filers is 1.35 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $291,000 | -7.0% | 6,601 | +4.1% | 0.00% | – |
| Q1 2021 | $313,000 | +17.2% | 6,343 | 0.0% | 0.00% | – |
| Q4 2020 | $267,000 | -9.5% | 6,343 | -1.6% | 0.00% | – |
| Q3 2020 | $295,000 | -35.6% | 6,443 | -29.4% | 0.00% | – |
| Q2 2020 | $458,000 | -26.5% | 9,129 | -24.7% | 0.00% | -100.0% |
| Q1 2020 | $623,000 | -16.6% | 12,121 | +0.2% | 0.00% | 0.0% |
| Q4 2019 | $747,000 | +2.9% | 12,092 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $726,000 | -28.8% | 12,092 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $1,020,000 | -50.0% | 12,092 | -50.7% | 0.00% | 0.0% |
| Q1 2019 | $2,039,000 | +135.7% | 24,503 | +100.6% | 0.00% | 0.0% |
| Q4 2018 | $865,000 | -17.1% | 12,214 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $1,044,000 | -38.7% | 12,214 | -16.8% | 0.00% | -50.0% |
| Q2 2018 | $1,702,000 | +6.8% | 14,683 | -25.5% | 0.00% | 0.0% |
| Q1 2018 | $1,594,000 | – | 19,697 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 511,186 | $43,686,000 | 11.23% |
| GREAT POINT PARTNERS LLC | 210,400 | $17,981,000 | 2.80% |
| ARMISTICE CAPITAL, LLC | 456,000 | $38,970,000 | 2.34% |
| Matarin Capital Management, LLC | 210,208 | $17,964,376,000 | 1.16% |
| Sapphire Star Partners LP | 8,168 | $698,000 | 0.70% |
| Granahan Investment Management | 103,320 | $8,830,000 | 0.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 867,500 | $74,137,000 | 0.44% |
| 361 CAPITAL LLC | 19,040 | $1,627,000 | 0.35% |
| ALGERT GLOBAL LLC | 17,922 | $1,532,000 | 0.33% |
| AlphaMark Advisors, LLC | 9,310 | $796,000 | 0.32% |